Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.33 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735234 | 0.92 | CYP11B1 (0.37) | SIRT2CYP11B1CYP11B2ENPP2ADA | |
| SCHEMBL7262693 | 0.90 | SIRT2 (0.32) | SIRT2TBXAS1ENPP2CYP2J2 | |
| SCHEMBL9518341 | 0.88 | FLT3 (0.38) | SIRT2 | |
| SCHEMBL10457151 | 0.85 | HPGD (0.39) | SIRT2CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL8865971 | 0.84 | KCNH2 (0.42) | SIRT2ADAMAPT | |
| SCHEMBL9489847 | 0.82 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2ENPP2ADA | |
| SCHEMBL1414901 | 0.82 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL1483017 | 0.81 | SIRT2 (0.39) | SIRT2CYP11B1CYP11B2LMNAMAPT | |
| SCHEMBL5682164 | 0.79 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2ADA | |
| SCHEMBL670904 | 0.79 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1681290-B9 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1681290-B1 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20090118512-A1 | Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One | SPEEDEL EXPERIMENTA AG (CH) | 2009-05-07 | — | — | US | disclosed |
| EP-2001850-A1 | PROCESS FOR PREPARING 6,7-DIHYDRO-5H-IMIDAZOÝ1,5-A¨PYRIDIN-8-ONE | Speedel Experimenta AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007113235-A1 | PROCESS FOR PREPARING 6,7-DIHYDRO-5H-IMIDAZO[1,5-A]PYRIDIN-8-ONE | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-7141598-B2 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1681290-A2 | Imidazole derivatives, production method thereof and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-1334106-B1 | IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1334106-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040484-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118512-A1 | Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One | ADH1A, ADH1C, ADH5 | SIRT2 1338/4885CYP11B1 700/4885CYP11B2 501/4885 |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | CYP17A1, CYP21A2, CYP19A1 | SIRT2 2146/4885CYP11B1 12/4885CYP11B2 21/4885 |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | SIRT2 4191/4885CYP11B1 2481/4885CYP11B2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.